These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8567570)

  • 1. ET-3 is extracted by and induces potent vasoconstriction in human splanchnic and renal vasculatures.
    Weitzberg E; Hemsén A; Lundberg JM; Ahlborg G
    J Appl Physiol (1985); 1995 Oct; 79(4):1255-9. PubMed ID: 8567570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues.
    Weitzberg E; Ahlborg G; Lundberg JM
    Biochem Biophys Res Commun; 1991 Nov; 180(3):1298-303. PubMed ID: 1953780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Big ET-1 infusion in man causes renal ET-1 release, renal and splanchnic vasoconstriction, and increased mean arterial blood pressure.
    Ahlborg G; Ottosson-Seeberger A; Hemsén A; Lundberg JM
    Cardiovasc Res; 1994 Oct; 28(10):1559-63. PubMed ID: 8001046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating endothelin-1 reduces splanchnic and renal blood flow and splanchnic glucose production in humans.
    Ahlborg G; Weitzberg E; Lundberg JM
    J Appl Physiol (1985); 1995 Jul; 79(1):141-5. PubMed ID: 7559211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional extraction of endothelins and conversion of big endothelin to endothelin-1 in the pig.
    Hemsén A; Pernow J; Lundberg JM
    Acta Physiol Scand; 1991 Mar; 141(3):325-34. PubMed ID: 1858505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin-1 infusion reduces splanchnic glucose production in humans.
    Ahlborg G; Weitzberg E; Lundberg JM
    J Appl Physiol (1985); 1994 Jul; 77(1):121-6. PubMed ID: 7961223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase inhibition potentiates the renal vascular response to endothelin-1 in humans.
    Ahlborg G; Lundberg JM
    J Appl Physiol (1985); 1998 Nov; 85(5):1661-6. PubMed ID: 9804567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulatory responses to endothelin-1 and nitric oxide with special reference to endotoxin shock and nitric oxide inhalation.
    Weitzberg E
    Acta Physiol Scand Suppl; 1993; 611():1-72. PubMed ID: 8379340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin sensitivity and big ET-1 conversion to ET-1 after ETA- or ETB-receptor blockade in humans.
    Ahlborg G; Lindström J
    J Appl Physiol (1985); 2002 Dec; 93(6):2112-21. PubMed ID: 12391119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men.
    Böhm F; Pernow J; Lindström J; Ahlborg G
    Clin Sci (Lond); 2003 Feb; 104(2):143-51. PubMed ID: 12546636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide-endothelin-1 interaction in humans.
    Ahlborg G; Lundberg JM
    J Appl Physiol (1985); 1997 May; 82(5):1593-600. PubMed ID: 9134909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation.
    Wagner OF; Vierhapper H; Gasic S; Nowotny P; Waldhäusl W
    Eur J Clin Invest; 1992 Apr; 22(4):277-82. PubMed ID: 1499643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splanchnic and renal vasoconstrictor and metabolic responses to neuropeptide Y in resting and exercising man.
    Ahlborg G; Weitzberg E; Sollevi A; Lundberg JM
    Acta Physiol Scand; 1992 Jun; 145(2):139-49. PubMed ID: 1636443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function.
    Gerbes AL; Møller S; Gülberg V; Henriksen JH
    Hepatology; 1995 Mar; 21(3):735-9. PubMed ID: 7875671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The C-terminal fragment of big endothelin-1 does not potentiate the vasoactive effects of endothelin-1.
    Ottosson-Seeberger A; Hemsén A; Lundberg JM; Ahlborg G
    Clin Physiol; 1998 Jan; 18(1):61-8. PubMed ID: 9545622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of Big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21).
    Hemsén A; Ahlborg G; Ottosson-Seeberger A; Lundberg JM
    Regul Pept; 1995 Feb; 55(3):287-97. PubMed ID: 7761628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and vascular effects of circulating endothelin-1 during moderately heavy prolonged exercise.
    Ahlborg G; Weitzberg E; Lundberg J
    J Appl Physiol (1985); 1995 Jun; 78(6):2294-300. PubMed ID: 7665432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional hemodynamics during postexercise hypotension. I. Splanchnic and renal circulations.
    Pricher MP; Holowatz LA; Williams JT; Lockwood JM; Halliwill JR
    J Appl Physiol (1985); 2004 Dec; 97(6):2065-70. PubMed ID: 15310744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of responses to sarafotoxins 6a and 6c in pulmonary and systemic vascular beds.
    Minkes RK; Bellan JA; Higuera TR; Kadowitz PJ
    Am J Physiol; 1992 Mar; 262(3 Pt 2):H852-61. PubMed ID: 1348398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and functional characterization of endothelin peptides with special reference to vascular effects.
    Hemsén A
    Acta Physiol Scand Suppl; 1991; 602():1-61. PubMed ID: 1659115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.